| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/02/2001 | WO2001055149A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid |
| 08/02/2001 | WO2001055147A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS |
| 08/02/2001 | WO2001055134A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 08/02/2001 | WO2001055131A2 Prodigiosin-derivatives as neoplastic and anti-viral agents |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055126A2 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin iii |
| 08/02/2001 | WO2001055121A1 Azepine derivatives |
| 08/02/2001 | WO2001055119A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 08/02/2001 | WO2001055117A1 Novel isoquinoline derivatives, preparation method and pharmaceutical compositions containing them |
| 08/02/2001 | WO2001055116A2 Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| 08/02/2001 | WO2001055115A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | WO2001055114A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 08/02/2001 | WO2001055112A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055097A1 Preparation of nitrogen mustard derivatives |
| 08/02/2001 | WO2001055092A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 08/02/2001 | WO2001054771A2 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054731A2 Ligand conjugates and methods for preparing same |
| 08/02/2001 | WO2001054724A1 Anticancer compositions |
| 08/02/2001 | WO2001054723A1 Therapeutic method for reducing angiogenesis |
| 08/02/2001 | WO2001054720A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants |
| 08/02/2001 | WO2001054717A1 Vaccine composition, process and methods |
| 08/02/2001 | WO2001054716A2 Genetically engineered tumor cell vaccines |
| 08/02/2001 | WO2001054707A2 Modification of surface proteins by aminopeptidase inhibitors |
| 08/02/2001 | WO2001054705A1 Cancer cell implantation inhibitors |
| 08/02/2001 | WO2001054702A1 Novel compounds |
| 08/02/2001 | WO2001054689A1 Laulimalide compounds as microtubule stabilizing agents |
| 08/02/2001 | WO2001054680A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054678A2 Combination therapy for cancer |
| 08/02/2001 | WO2001054672A2 Closure of bacterial ghosts |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001054666A1 Liposomes containing an entrapped compound in supersaturated solution |
| 08/02/2001 | WO2001016114A3 Heterocyclic compounds and methods for modulating cxcr3 function |
| 08/02/2001 | WO2001014548A3 New g-protein coupled receptor and dna sequences thereof |
| 08/02/2001 | WO2001012189A8 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 08/02/2001 | WO2001005826A3 Chimeric polypeptides of serum albumin and uses related thereto |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2001004155A3 Feline interleukin-12 as an immune stimulant |
| 08/02/2001 | WO2001000828A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/02/2001 | WO2000076971A3 Serine protease inhibitors |
| 08/02/2001 | WO2000067801A3 Prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| 08/02/2001 | WO2000066564A8 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 08/02/2001 | WO2000066175A3 Conjugates as therapies for cancer and prostate diseases |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO2000047603A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | WO2000046391A9 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 08/02/2001 | WO1999049025A3 Human vault rna |
| 08/02/2001 | US20010011136 Anticancer agents |
| 08/02/2001 | US20010011135 Anticancer agents |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011100 Use of an angiogenesis inhibitor as a lead compound in drug development |
| 08/02/2001 | US20010011093 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010010935 Useful in treating stem cells in a patient undergoing chemotherapy |
| 08/02/2001 | US20010010934 Polypeptides that regulate epithelial specific gene expression; hypoproliferative disorders; medical diagnosis |
| 08/02/2001 | US20010010933 Configuration; vectors; recombinants |
| 08/02/2001 | US20010010928 Protozoan expression system |
| 08/02/2001 | US20010010924 Inflammation, arthritis, septicemia, brain injury, autoimmune (inflammatory bowel, psoriasis)/bone/acute respiratory diseases, restenosis, AIDS, cancer (lympho-proliferative disorders, atheroscleosis, and Alzheimer's |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | US20010010911 Polynucleotide |
| 08/02/2001 | US20010010822 For pharmaceutical preparations |
| 08/02/2001 | US20010010821 For treatment of gastrointestinal disorders |
| 08/02/2001 | EP1144431A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | DE10011926A1 Genetisch veränderte Fibroblastenzellen Genetically modified fibroblast cells |
| 08/02/2001 | DE10004157A1 New pyridyl- or pyrimidinyl-substituted bicyclic pyrrole derivatives, are cyclokine release inhibitors useful for treating immune system-related disorders, e.g. cancer, multiple sclerosis or arthritis |
| 08/02/2001 | DE10003620A1 Non-aqueous solution or suspension of 5-aminolevulinic acid, is useful in the treatment or diagnosis of tumor diseases or psoriasis by photodynamic therapy |
| 08/02/2001 | DE10003241A1 Verschließen von Bakterienghosts Closing bacterial ghosts |
| 08/02/2001 | CA2423122A1 Closure of bacterial ghosts |
| 08/02/2001 | CA2398743A1 Novel mhc class ii restricted t cell epitopes from the cancer antigen, ny eso-1 |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398660A1 Human cyr61 |
| 08/02/2001 | CA2398655A1 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin iii |
| 08/02/2001 | CA2398643A1 Novel compounds |
| 08/02/2001 | CA2398564A1 Nuclear hormone receptors |
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398548A1 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398514A1 Liposomes containing an entrapped compound in supersaturated solution |
| 08/02/2001 | CA2398503A1 Therapeutic method for reducing angiogenesis |
| 08/02/2001 | CA2398435A1 Novel ligands and methods for preparing same |
| 08/02/2001 | CA2398430A1 Human protein kinases and protein kinase-like enzymes |
| 08/02/2001 | CA2398427A1 Cancer cell implantation inhibitors |
| 08/02/2001 | CA2398396A1 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398358A1 The neurosteroid dhea as a marker for neuropathologies |
| 08/02/2001 | CA2398227A1 17 human secreted proteins |
| 08/02/2001 | CA2398173A1 Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases |
| 08/02/2001 | CA2398104A1 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 08/02/2001 | CA2398003A1 Phosphodiesterases |
| 08/02/2001 | CA2397643A1 Vector constructs for gene-therapy mediated radionuclide therapy of undifferentiated and medullary thyroid carcinomas and non-thyroidal tumours and the metastases thereof |
| 08/02/2001 | CA2397523A1 Combination therapy for cancer |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2396884A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2395832A1 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 08/01/2001 | EP1120464A2 Stabilizing peptides, polypeptides and antibodies which include them |
| 08/01/2001 | EP1120114A2 Compositions and methods for treating conditions responsive to estrogen |
| 08/01/2001 | EP1120113A2 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormone |
| 08/01/2001 | EP1119629A2 Oxidoreductase molecules |
| 08/01/2001 | EP1119623A1 Mage-a3 peptides presented by hla class ii molecules |
| 08/01/2001 | EP1119622A2 Bax-mediated apoptosis modulating reagents and methods |